EMERGENT BIOSOLUTIONS INC. Income (Loss) from Continuing Operations, Per Diluted Share
EMERGENT BIOSOLUTIONS INC. (EBS) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$0.07 per share for the 3-month period ending 2018-12-31, per its 10-K filed 2019-02-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2019-02-22
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per diluted share for the quarter ending 2018-12-31 was -$0.07, a 110.45% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per diluted share for the quarter ending 2018-09-30 was $0.41, a 39.71% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per diluted share for the quarter ending 2018-06-30 was $0.98, a 790.91% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per diluted share for the quarter ending 2018-03-31 was -$0.10, a 143.48% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per diluted share for fiscal 2018 was $1.22, a 28.65% decline from fiscal 2017.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per diluted share for fiscal 2017 was $1.71, a 26.67% increase from fiscal 2016.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per diluted share for fiscal 2016 was $1.35, a 33.17% decline from fiscal 2015.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, per diluted share for fiscal 2015 was $2.02, a 60.32% increase from fiscal 2014.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$0.07 10-K · filed 2019-02-22 | $1.22 10-K · filed 2019-02-22 | ||
| 2018-09-30 | $0.41 10-K · filed 2019-02-22 | |||
| 2018-06-30 | $0.98 10-K · filed 2019-02-22 | |||
| 2018-03-31 | -$0.10 10-K · filed 2019-02-22 | |||
| 2017-12-31 | $0.67 10-K · filed 2019-02-22 | $1.71 10-K · filed 2019-02-22 | ||
| 2017-09-30 | $0.68 10-K · filed 2019-02-22 | $1.03 10-Q · filed 2017-11-03 | ||
| 2017-06-30 | $0.11 10-K · filed 2019-02-22 | $0.35 10-Q · filed 2017-08-04 | ||
| 2017-03-31 | $0.23 10-K · filed 2019-02-22 | |||
| 2016-12-31 | $0.67 10-K · filed 2018-02-23 | $1.35 10-K · filed 2019-02-22 | ||
| 2016-09-30 | $0.43 10-K · filed 2018-02-23 | $0.68 10-Q · filed 2017-11-03 | ||
| 2016-06-30 | -$0.05 10-K · filed 2018-02-23 | $0.24 10-Q · filed 2017-08-04 | ||
| 2016-03-31 | $0.26 10-K · filed 2018-02-23 | |||
| 2015-12-31 | $0.90 10-K · filed 2017-02-28 | $2.02 10-K · filed 2018-02-23 | ||
| 2015-09-30 | $0.90 10-K · filed 2017-02-28 | $1.11 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | $0.50 10-K · filed 2017-02-28 | |||
| 2015-03-31 | -$0.42 10-K · filed 2017-02-28 | |||
| 2014-12-31 | $1.26 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |